CHMP recommends Sanofi’s Enjaymo, Agios’ Pyrukynd and ADC’s Zynlonta 

EMA’s CHMP recommended seven new medicines and label extensions for 11 previously approved drugs at its September meeting, including positive opinions for Sanofi’s Enjaymo, Agios’ Pyrukynd and ADC’s Zynlonta.

The agency recommended Enjaymo sutimlimab from Sanofi (Euronext:SAN; NASDAQ:SNY) for cold agglutinin disease, a rare autoimmune hemolytic anemia. If approved, the C1 protein inhibitor would be the first treatment for cold agglutinin disease in Europe. FDA approved Enjaymo in February...